Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Pfizer (PFE)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ultragenyx Pharmaceutical (RARE – Research Report) and Pfizer (PFE – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ultragenyx Pharmaceutical (RARE)
Morgan Stanley analyst Maxwell Skor maintained a Buy rating on Ultragenyx Pharmaceutical yesterday and set a price target of $50.00. The company’s shares closed last Tuesday at $24.80.
According to TipRanks.com, Skor is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ultragenyx Pharmaceutical with a $60.31 average price target, which is a 142.0% upside from current levels. In a report issued on January 23, Wells Fargo also maintained a Buy rating on the stock with a $45.00 price target.
See today’s best-performing stocks on TipRanks >>
Pfizer (PFE)
In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Hold rating on Pfizer, with a price target of $27.00. The company’s shares closed last Tuesday at $25.77.
According to TipRanks.com, Flynn is a 5-star analyst with an average return of
Currently, the analyst consensus on Pfizer is a Moderate Buy with an average price target of $28.53, implying a 12.5% upside from current levels. In a report released yesterday, TipRanks – Anthropic also downgraded the stock to Hold with a $29.00 price target.
